Birdwatch Note Rating
2023-12-12 22:08:20 UTC - NOT_HELPFUL
Rated by Participant: F592DC8752A5FF37A1CBEF21BF2B36A307F8721AB08DA80A157F869B91BDCB5B
Participant Details
Original Note:
The approval is based on positive clinical data from several ARCT-154 studies, including an ongoing 16,000 subject efficacy study performed in Vietnam as well as a Phase 3 COVID-19 booster trial. https://biomelbourne.org/japans-ministry-of-health-labour-and-welfare-approves-csl-and-arcturus-therapeutics-arct-154-the-first-self-amplifying-mrna-vaccine-approved-for-covid-in-adults/
All Note Details